MCK vs. COR, CAH, ZTS, BDX, GILD, HCA, GSK, BMY, EW, and DXCM
Should you be buying McKesson stock or one of its competitors? The main competitors of McKesson include Cencora (COR), Cardinal Health (CAH), Zoetis (ZTS), Becton, Dickinson and Company (BDX), Gilead Sciences (GILD), HCA Healthcare (HCA), GSK (GSK), Bristol-Myers Squibb (BMY), Edwards Lifesciences (EW), and DexCom (DXCM). These companies are all part of the "medical" sector.
Cencora (NYSE:COR) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.
McKesson has a net margin of 0.99% compared to McKesson's net margin of 0.69%. McKesson's return on equity of 323.23% beat Cencora's return on equity.
Cencora has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.
97.5% of Cencora shares are owned by institutional investors. Comparatively, 85.1% of McKesson shares are owned by institutional investors. 15.8% of Cencora shares are owned by company insiders. Comparatively, 0.2% of McKesson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
McKesson received 209 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.07% of users gave McKesson an outperform vote while only 65.06% of users gave Cencora an outperform vote.
Cencora presently has a consensus price target of $224.40, suggesting a potential downside of 2.11%. McKesson has a consensus price target of $536.71, suggesting a potential upside of 1.04%. Given Cencora's stronger consensus rating and higher possible upside, analysts plainly believe McKesson is more favorable than Cencora.
Cencora pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. McKesson pays an annual dividend of $2.48 per share and has a dividend yield of 0.5%. Cencora pays out 22.2% of its earnings in the form of a dividend. McKesson pays out 11.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cencora has raised its dividend for 1 consecutive years and McKesson has raised its dividend for 16 consecutive years.
McKesson has higher revenue and earnings than Cencora. McKesson is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.
In the previous week, McKesson had 16 more articles in the media than Cencora. MarketBeat recorded 31 mentions for McKesson and 15 mentions for Cencora. Cencora's average media sentiment score of 0.46 beat McKesson's score of 0.29 indicating that McKesson is being referred to more favorably in the news media.
Summary
McKesson beats Cencora on 14 of the 20 factors compared between the two stocks.
Get McKesson News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MCK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
McKesson Competitors List
Related Companies and Tools
